Literature DB >> 18524556

Palliative radiotherapy for women with breast cancer.

B Danielson1, M Winget, Z Gao, B Murray, R Pearcey.   

Abstract

AIMS: Palliative radiotherapy (PRT) plays an important role in women with metastatic breast cancer. However, not all cancer patients with an indication for PRT receive it. The aim of this study was to measure the use of PRT for women who have died of breast cancer in the Canadian province of Alberta, and to identify factors that might affect this use.
MATERIALS AND METHODS: All women who died of breast cancer in Alberta between 2000 and 2004 were identified from the Alberta Cancer Registry. PRT, defined as any radiotherapy given with palliative intent, was abstracted from the radiotherapy databases of the treatment facilities of the Alberta Cancer Board (ACB). The variables evaluated were: age at death, regional health authority (RHA), driving distance to nearest radiotherapy facility, receipt of initial treatment at an ACB facility, receipt of radiotherapy as part if initial treatment, residence in a city with an ACB facility, residence in a city with radiotherapy facilities or visiting radiation oncologists, median household income, and municipality population. Backwards stepwise logistic regression was used to determine the final set of predictor variables for the use of PRT.
RESULTS: In total, 1906 women were identified as having died of breast cancer between 2000 and 2004, inclusive. Of these, 50.4% received at least one course of PRT. Factors associated with not receiving PRT in the final multiple logistic regression model for women who lived outside of the cities with radiotherapy facilities were: age>75 years, community size>10,000, median income<$47,000, and residence in RHA 4. For women living in cities with radiotherapy facilities, only age was significant.
CONCLUSIONS: There are many factors that influence the receipt of PRT in Alberta that are unrelated to patient need. The education of physicians and patients, as well as the establishment of more radiotherapy facilities, will help to improve the use of PRT.

Entities:  

Mesh:

Year:  2008        PMID: 18524556     DOI: 10.1016/j.clon.2008.04.013

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  6 in total

1.  Variation in the use of palliative radiotherapy at end of life: examining demographic, clinical, health service, and geographic factors in a population-based study.

Authors:  M Ruth Lavergne; Grace M Johnston; Jun Gao; Trevor Jb Dummer; Dorianne E Rheaume
Journal:  Palliat Med       Date:  2010-10-11       Impact factor: 4.762

2.  Breast cancer in Zimbabwe: patterns of care and correlates of adherence in a national referral hospital radiotherapy center cohort from 2014 to 2018.

Authors:  Shekinah Nefreteri Cluff Elmore; Melinda Mushonga; Hari Subramaniam Iyer; Caroline Kanda; Shirley Chibonda; Fallon Chipidza; Rudo Makunike Mutasa; David Muchuweti; Edwin G Muguti; Aspect Maunganidze; Ntokozo Ndlovu; Jennifer Ruth Bellon; Anna Mary Nyakabau
Journal:  Cancer Med       Date:  2021-05-10       Impact factor: 4.452

3.  Variations in intensity of end-of-life cancer therapy by cancer type at a Canadian tertiary cancer centre between 2003 and 2010.

Authors:  Petra Grendarova; Aynharan Sinnarajah; Theresa Trotter; Cynthia Card; Jackson S Y Wu
Journal:  Support Care Cancer       Date:  2015-03-07       Impact factor: 3.603

4.  Determine the therapeutic role of radiotherapy in administrative data: a data mining approach.

Authors:  Jina Zhang-Salomons; Greg Salomons
Journal:  BMC Med Res Methodol       Date:  2015-02-03       Impact factor: 4.615

5.  [Lost to follow-up in radiotherapy: experience of the National Institute of Oncology in Morocco].

Authors:  Imane Mezouri; Hanane Chenna; Sara Bellefqih; Hanan Elkacemi; Tayeb Kebdani; Noureddine Benjaafar
Journal:  Pan Afr Med J       Date:  2014-09-08

Review 6.  Barriers to accessing radiation therapy in Canada: a systematic review.

Authors:  Caitlin Gillan; Kaleigh Briggs; Alejandro Goytisolo Pazos; Melanie Maurus; Nicole Harnett; Pamela Catton; David Wiljer
Journal:  Radiat Oncol       Date:  2012-10-12       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.